Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)

NCT00462488 is registered in ClinicalTrials.gov with Sesen Bio, Inc. as lead sponsor.

NCT NCT00462488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00462488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)
Lead sponsor
Sesen Bio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
October 31, 2009
Enrollment
46 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder neoplasms, bladder tumors, urinary bladder cancer